Status:
COMPLETED
Sentinel Node After Neoadjuvancy In Node-Positive Breast Cancer
Lead Sponsor:
Hospital Clinic of Barcelona
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
The status of the axillary lymph nodes is one of the main prognostic factors in breast cancer (BC). SLNB is currently the standard staging method for patients with clinically node-negative (cN0) breas...
Detailed Description
Breast cancer (BC) is the most common malignant tumor and the one that causes the highest number of deaths among women around the world. In Spain some 25,000 new cases are diagnosed per year, which re...
Eligibility Criteria
Inclusion
- Age equal to or greater than 18 years
- Patients with a diagnosis of T1-T3 primary infiltrating breast carcinoma
- Axillary clinical involvement (cN +)
- Confirmation by FNAC or BAG of lymph node involvement
- Candidates for neoadjuvant chemotherapy including anthracyclines and taxanes
Exclusion
- T4 tumors
- Supra / infraclavicular lymph node or internal mammary chain (cN3) involvement
- Previous ipsilateral breast or axillary surgery
- Distant metastasis at diagnosis (M1)
Key Trial Info
Start Date :
June 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2021
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04865549
Start Date
June 1 2016
End Date
January 1 2021
Last Update
April 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Clínic de Barcelona
Barcelona, Spain, 08036